<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00676819</url>
  </required_header>
  <id_info>
    <org_study_id>ANA-1416</org_study_id>
    <nct_id>NCT00676819</nct_id>
  </id_info>
  <brief_title>Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes</brief_title>
  <official_title>Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Soluble Insulin in Geriatric Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate if the
      pharmacodynamic / pharmacokinetic properties of insulin aspart and human soluble insulin are
      different in elderly (65 years of age or older) with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2002</start_date>
  <completion_date type="Actual">July 19, 2002</completion_date>
  <primary_completion_date type="Actual">July 19, 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose infusion rate</measure>
    <time_frame>in the time period from 0 to 120 min after administration of trial products (AUCGIR(0-120 min))</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCGIR(0-300 min) the area under the GIR profile</measure>
    <time_frame>in the interval 0-300 minutes post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCGIR(0 min-end of clamp) the area under the GIR profile</measure>
    <time_frame>in the interval 0-600 minutes post dosing (or 0 min until termination of the glucose clamp if abandoned early because of high blood glucose values)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCGIR(300min-end of clamp) the area under the GIR profile</measure>
    <time_frame>in the interval 300-600 minutes post dosing (or 300 min until termination of the glucose clamp if abandoned early because of high blood glucose values)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIRmax: the maximal GIR value</measure>
    <time_frame>tmax, GIR: the time to maximal GIR value</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>early and late t50%, GIR</measure>
    <time_frame>the time to early and late half-maximal GIR value</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCINS(0-60 min) the area under the serum insulin (or serum insulin aspart) profile</measure>
    <time_frame>in the interval 0-60 minutes post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCINS(0-300 min) the area under the serum insulin (or serum insulin aspart) profile</measure>
    <time_frame>in the interval 0-300 minutes post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCINS(0min-end of clamp) the area under the serum insulin (or serum insulin aspart) profile</measure>
    <time_frame>in the interval 0-600 minutes post dosing (or 0 min until termination of the glucose clamp if abandoned early because of high blood glucose values)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCINS(300min-end of clamp) the area under the serum insulin (or serum insulin aspart) profile</measure>
    <time_frame>in the interval 300-600 minutes post dosing (or 300 min until termination of the glucose clamp if abandoned early because of high blood glucose values)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ins: the maximal serum insulin (or serum insulin aspart) concentration</measure>
  </secondary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <other_name>ANA</other_name>
    <other_name>NovoRapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human insulin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Duration of diabetes for at least 12 months

          -  Current treatment with human insulin or insulin analogues for at least 6 months

          -  BMI equal to or below 35 kg/m2

          -  HbA1c equal to or greater than 10.0 %

          -  No clinically significant cardiovascular event as judged by the Investigator within
             the last 6 months prior to the study

        Exclusion Criteria:

          -  History of any illness that, in the opinion of the Investigator might confound the
             results of the study or pose additional risk in administering the trial products to
             the subject

          -  Current treatment with systemic corticosteroids

          -  Any positive reaction of drug of abuse or alcohol screen

          -  Cardiac problems defined as: decompensated heart failure and/or angina pectoris

          -  Uncontrolled treated/untreated hypertension as judged by the Investigator or blood
             pressure &gt; 180 mm Hg systolic and/or &gt; 110 mm Hg diastolic

          -  Known or suspected allergy to trial product or related products

          -  Blood donation of more than 500 ml within the last 12 weeks

          -  The receipt of any investigational drug within 4 weeks prior to this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Köln</city>
        <zip>50825</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Krones R, Schütte C, Heise T. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Diabetes Obes Metab. 2009 Jan;11(1):41-4. doi: 10.1111/j.1463-1326.2008.00988.x.</citation>
    <PMID>19120432</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2008</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

